Press release - ABNewswire - PD-1 NSCLC Pipeline Assessment, 2024 Updates | In-depth Insights into the Emerging Drugs, Latest FDA, EMA, and PMDA Approvals, Clinical Trials, and Treatment Outlook | Genor Biopharma, Shandong Boan - published on openPR.com